RV-directed therapy
Current treatment for pulmonary vascular disease acts on the pulmonary circulation; the right ventricle improves if afterload falls. Whether the failing RV can be treated directly — targeting its fibrosis, metabolism or contractility — is the central open question, and no RV-specific therapy is established.
Antiproliferative and disease-modifying approaches
The shift in pulmonary arterial hypertension from vasodilator therapy toward agents targeting vascular remodelling represents a move from symptomatic to disease-modifying treatment. Whether remodelling can be reversed rather than slowed, and how early intervention must occur, are the questions following from it.
Earlier detection
RV failure presents late because adaptation masks it. Work on earlier markers — strain imaging, biomarkers, exercise haemodynamics — aims at identifying the transition from adaptive to maladaptive remodelling while it may still be reversible.
The neglected populations
Right heart involvement in heart failure with preserved ejection fraction, in chronic lung disease and in congenital heart disease is common and under-studied relative to its prevalence. Group 2 and group 3 pulmonary hypertension have far less trial evidence than group 1, and treatments established in group 1 have not generally transferred — a point where extrapolation has caused harm.
Methodological direction
Outcome measures are contested. Six-minute walk distance has limited responsiveness and uncertain patient relevance; composite endpoints including clinical worsening, and patient-reported outcomes, are increasingly used. Core outcome set work would help comparability across trials.
In short
What to take from this.
- No RV-specific therapy is established — current treatment acts on afterload.
- Do not extrapolate group 1 PAH treatments to groups 2 and 3.
- Six-minute walk distance is a weak primary endpoint.
Sources
- Established pulmonary hypertension treatment literature
- Outcome measure literature in pulmonary vascular disease
This page reflects established understanding as at mid-2026 and is not a current-awareness service. Clinical and regulatory positions change; verify anything decision-relevant against a current source.
Related